- Home
- MDWD vs EHI Comparison
MDWD vs EHI Comparison
Compare MDWD & EHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- EHI
- Stock Information
- Founded
- MDWD 2000
- EHI 2003
- Country
- MDWD Israel
- EHI United States
- Employees
- MDWD N/A
- EHI N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- EHI Investment Managers
- Sector
- MDWD Health Care
- EHI Finance
- Exchange
- MDWD Nasdaq
- EHI Nasdaq
- Market Cap
- MDWD 184.8M
- EHI N/A
- IPO Year
- MDWD 2014
- EHI N/A
- Fundamental
- Price
- MDWD $19.02
- EHI $6.61
- Analyst Decision
- MDWD Strong Buy
- EHI
- Analyst Count
- MDWD 1
- EHI 0
- Target Price
- MDWD $25.00
- EHI N/A
- AVG Volume (30 Days)
- MDWD 61.7K
- EHI 44.5K
- Earning Date
- MDWD 11-26-2024
- EHI 01-01-0001
- Dividend Yield
- MDWD N/A
- EHI 11.54%
- EPS Growth
- MDWD N/A
- EHI N/A
- EPS
- MDWD N/A
- EHI N/A
- Revenue
- MDWD $19,720,000.00
- EHI N/A
- Revenue This Year
- MDWD $10.37
- EHI N/A
- Revenue Next Year
- MDWD $26.36
- EHI N/A
- P/E Ratio
- MDWD N/A
- EHI N/A
- Revenue Growth
- MDWD N/A
- EHI N/A
- 52 Week Low
- MDWD $11.04
- EHI $6.00
- 52 Week High
- MDWD $24.00
- EHI $7.75
- Technical
- Relative Strength Index (RSI)
- MDWD 61.79
- EHI 45.46
- Support Level
- MDWD $15.80
- EHI $6.52
- Resistance Level
- MDWD $18.25
- EHI $6.65
- Average True Range (ATR)
- MDWD 0.88
- EHI 0.07
- MACD
- MDWD 0.07
- EHI -0.00
- Stochastic Oscillator
- MDWD 95.27
- EHI 50.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.